- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07827222
Gemini Flash 3.6 Versus Human Observers for FIGO-Based Interpretation of Intrapartum Cardiotocography
Gemini Flash 3.6 Versus Human Observers for FIGO-Based Interpretation of Intrapartum Cardiotocography: A Diagnostic Accuracy Study
Cardiotocography (CTG) is the standard method for monitoring fetal heart rate and uterine contractions during labor to detect signs of fetal hypoxia. However, human CTG interpretation is often subjective and subject to high interobserver variability, even among experienced clinicians. Multimodal artificial intelligence (AI) models have emerged as potential diagnostic aids capable of evaluating CTG tracings. This prospective diagnostic accuracy study aims to evaluate the diagnostic performance of Gemini Flash 3.6 in interpreting intrapartum CTG recordings according to the 2015 International Federation of Gynecology and Obstetrics (FIGO) guidelines, and to compare its accuracy directly against independent human expert obstetricians.
Participants include pregnant women admitted in active labor at term with a singleton cephalic pregnancy undergoing continuous CTG monitoring. De-identified digital images of the final 60 minutes of CTG tracing prior to delivery will be independently evaluated by Gemini Flash 3.6 and three expert obstetricians. Each evaluator will classify the tracings into one of three FIGO categories: Normal, Suspicious, or Pathological. All evaluators will be blinded to clinical details, delivery outcomes, and other observers' interpretations.
The primary objective is to assess the diagnostic sensitivity of Gemini Flash 3.6 in identifying neonates with a 5-minute Apgar score less than 7. Secondary objectives include comparing the diagnostic performance of the AI model with that of individual expert obstetricians, measuring interobserver agreement among all raters, and assessing associations with 1-minute Apgar scores and umbilical artery blood gas parameters. The AI model will be used solely as an investigational research tool, and its evaluations will not be available to the clinical team or used to guide patient care.
Aperçu de l'étude
Statut
Les conditions
Type d'étude
Inscription (Estimé)
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Méthode d'échantillonnage
Population étudiée
La description
Inclusion Criteria:
- Singleton pregnancy
- Gestational age 37+0 weeks or greater
- Cephalic fetal presentation
- Admission to the labor ward in active labor
- Continuous intrapartum cardiotocography (CTG) monitoring
- Availability of an interpretable CTG tracing immediately preceding delivery
- Availability of documented 1-minute and 5-minute Apgar scores
- Written informed consent obtained prior to enrollment
Exclusion Criteria:
- Multiple pregnancy
- Major fetal congenital anomalies
- Antepartum stillbirth
- Elective cesarean delivery performed before the onset of labor without an adequate intrapartum CTG tracing
- CTG tracing with inadequate technical quality, including signal loss of 15% or greater
- Missing 5-minute Apgar score
- Technical problems preventing standardized CTG image preparation or interpretation
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Cohortes et interventions
Groupe / Cohorte |
|---|
|
Intrapartum CTG Monitoring Cohort
Women with singleton term pregnancies (gestational age ≥ 37 + 0 weeks) in cephalic presentation admitted to the labor ward in active labor who undergo routine continuous intrapartum cardiotocography (CTG) monitoring immediately preceding delivery.
De-identified digital CTG tracings from this cohort are independently evaluated by Gemini Flash 3.6 and three expert obstetricians according to the 2015 FIGO consensus guidelines, and validated against neonatal outcomes including 1-minute and 5-minute Apgar scores as well as umbilical artery blood-gas analysis where available.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Sensitivity of Gemini Flash 3.6 for Identifying Neonates With a 5-Minute Apgar Score Less Than 7
Délai: 5 minutes after birth
|
Sensitivity is defined as the percentage of neonates with a confirmed 5-minute Apgar score less than 7 who are correctly identified as having a "Pathological" CTG tracing by Gemini Flash 3.6.
Intrapartum CTG tracings from the final 60 minutes of labor immediately preceding delivery are interpreted according to the 2015 FIGO guidelines.
For binary diagnostic performance analysis, a "Pathological" CTG represents a positive test result, while "Normal" and "Suspicious" CTGs represent negative test results.
Sensitivity is calculated as [True Positives / (True Positives + False Negatives)] * 100 and reported with a 95% confidence interval.
|
5 minutes after birth
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Maladies urogénitales
- Maladies urogénitales féminines et complications de la grossesse
- Complications de grossesse
- Maladies fœtales
- Signes et symptômes respiratoires
- Hypoxie
- Maladies et anomalies congénitales, héréditaires et néonatales
- Conditions pathologiques, signes et symptômes
- Signes et symptômes
- Détresse fœtale
- Hypoxie fœtale
Autres numéros d'identification d'étude
- Gemini Flash vs Human FIGO CTG
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .